Basic information Safety Supplier Related

4-[[3,4-(METHYLENEDIOXY)BENZYL]AMINO]-6-CHLOROQUINAZOLINE

Basic information Safety Supplier Related

4-[[3,4-(METHYLENEDIOXY)BENZYL]AMINO]-6-CHLOROQUINAZOLINE Basic information

Product Name:
4-[[3,4-(METHYLENEDIOXY)BENZYL]AMINO]-6-CHLOROQUINAZOLINE
Synonyms:
  • MBCQ
  • 4-[[3,4-(METHYLENEDIOXY)BENZYL]AMINO]-6-CHLOROQUINAZOLINE
  • N-(1,3-BENZODIOXOL-5-YLMETHYL)-6-CHLORO-4-QUINAZOLINAMINE
  • 4-Quinazolinamine, N-(1,3-benzodioxol-5-ylmethyl)-6-chloro-
  • v2330
  • cGMP-PDE,inhibit,arteries,PGF2α,Inhibitor,MBCQ,Phosphodiesterase (PDE),coronary
  • N-(Benzo[d][1,3]dioxol-5-ylmethyl)-6-chloroquinazolin-4-amine
CAS:
150450-53-6
MF:
C16H12ClN3O2
MW:
313.74
Mol File:
150450-53-6.mol
More
Less

4-[[3,4-(METHYLENEDIOXY)BENZYL]AMINO]-6-CHLOROQUINAZOLINE Chemical Properties

storage temp. 
2-8°C
solubility 
DMSO: soluble5mg/mL (clear solution)
form 
powder
color 
white to beige
More
Less

Safety Information

WGK Germany 
3
More
Less

4-[[3,4-(METHYLENEDIOXY)BENZYL]AMINO]-6-CHLOROQUINAZOLINE Usage And Synthesis

Uses

MBCQ is a selective inhibitor of cGMP-specific phosphodiesterase.

Definition

ChEBI: N-(1,3-benzodioxol-5-ylmethyl)-6-chloro-4-quinazolinamine is a member of quinazolines.

Biological Activity

mbcq is a cgmp-specific phosphodiesterase pde5 inhibitor.the phosphodiesterase type 5 inhibitor (pde5 inhibitor) is an agent used to inhibit the degradative action of cgmp-specific pde5 on cyclic gmp in the smooth muscle cells lining the blood vessels supplying the corpus cavernosum of the penis. pde5 drugs are used in the treatment of erectile dysfunction and were the first effective oral treatment for this condition. sinve pde5 is also present in the arterial wall smooth muscle within the lungs, pde5 inhibitors have also been applied for the pulmonary hypertension treatment.

in vitro

in previous study, it was found that the addition of mbcq to the blood vessle samples could lead to an 80 to 85% inhibition of pde activity, indicating that most of the activity present in these blood vessels could be attributed to pde5. [1].

in vivo

in animal rat study, tolerance was induced by continuous exposure to glyceryl trinitrate (gtn) for 48 h. results showed that mbcq could significantly decrease the ec(50) values for gtn-induced relaxation in both tolerant and nontolerant tissues, but with the greatest relative shift showing in tolerant veins. moreover, mbcq could also increase the vasodilator potency of a nitric oxide donor (1,1-diethyl-2-hydroxy-2-nitrosohydrazine). a significant increase in cgmp pde activity was found in tolerant femoral vein, whereas pde activity was unchanged in femoral artery [1].

References

[1] macpherson jd, gillespie td, dunkerley ha, maurice dh, bennett bm. inhibition of phosphodiesterase 5 selectively reverses nitrate tolerance in the venous circulation. j pharmacol exp ther. 2006 apr;317(1):188-95.

4-[[3,4-(METHYLENEDIOXY)BENZYL]AMINO]-6-CHLOROQUINAZOLINESupplier

Shanghai EFE Biological Technology Co., Ltd.
Tel
021-65675885 18964387627
Email
info@efebio.com
Tianjin Kailiqi Biotechnology Co., Ltd.
Tel
15076683720
Email
klq@cw-bio.com
Shanghai Rechem science Co., Ltd.
Tel
21-31433387 15618786686
Email
sales@rechemscience.com
Shanghai SuperLan Chemcial Technique Centre
Tel
021-2022843681 15618226720
Email
lucy@atkchemical.com
MQ (shanghai) Pharmaceuticals Co., Ltd.
Tel
13761635123
Email
1014988033@qq.com